Indaptus Therapeutics, Inc. INDP

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

are a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy.

We have evolved from more than a century of immunotherapy advances. Our approach is based on the hypothesis that efficient activation

of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package

of immune system activating signals that can be administered safely intravenously. Our patented technology is composed of single strains

Last close 3.16 2026-10-23
Market cap $421.0M 2026-06-30 share count
52-week range 0.92 - 5.96

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-21.58

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019
R&D $9.3M$7.3M$7.6M$6.3M$2.5M$2.7M—
SG&A $10.5M$8.1M$8.8M$8.6M$5.2M$944.2K—
Total operating expenses $19.8M$15.4M$16.4M$14.9M$7.7M$3.6M—
Operating income -$19.8M-$15.4M-$16.4M-$14.9M-$7.7M-$3.6M—
Pre-tax income -$20.8M-$15.0M-$15.4M-$14.3M-$7.7M-$3.6M—
Income tax $1.7K$1.7K$2.5K$30$1.6K$800—
Net income -$20.8M-$15.0M-$15.4M-$14.3M-$7.7M-$3.6M—
EPS, basic -21.58-44.96-1.83-1.73-1.89——
EPS, diluted -21.58-44.96-1.83-1.73-1.89-1.84—
Shares, diluted (wtd. avg.) 966,124334,1338.4M8.3M4.1M——

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents $8.5M$5.8M$13.4M$9.6M$39.1M$1.6M—
Short-term investments ———$16.8M———
Total current assets $9.3M$6.6M$14.0M$27.2M$40.4M$1.7M—
Property, plant and equipment ——$735$2.0K$3.8K$1.3K—
Total assets $9.3M$7.3M$14.9M$28.1M$40.6M$1.8M—
Accounts payable $544.1K$870.2K$806.0K$1.4M$2.5M$156.0K—
Total current liabilities $6.2M$3.4M$2.8M$3.4M$4.6M$2.0M—
Total liabilities —$3.4M$2.8M$3.4M$4.7M$2.0M—
Retained earnings -$81.3M-$60.4M-$45.4M-$30.0M-$15.7M-$8.0M—
Total equity $3.2M$3.9M$12.1M$24.6M$35.9M-$237.7K$3.2M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Operating cash flow -$14.8M-$12.3M-$13.4M-$13.1M-$11.3M-$3.3M—
Depreciation and amortisation —$735$1.3K$1.8K$1.4K$852—
Stock-based compensation $1.4M$2.3M$3.0M$3.0M$1.5M$140.0K—
Capital expenditure ————$3.9K——
Investing cash flow ——$17.1M-$16.4M$447.7K——
Financing cash flow $17.5M$4.7M——$48.3M$1.2M—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-033545.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -30M -20M -10M 0 Net income, FY2020: -3.6M Net income, FY2021: -7.7M Net income, FY2022: -14.3M Net income, FY2023: -15.4M Net income, FY2024: -15M Net income, FY2025: -20.8M FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — — — — — — —
Gross profit — — — — — — —
Net income — -$3.6M -$7.7M -$14.3M -$15.4M -$15.0M -$20.8M

Recent filings and events

  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Material agreement signed Item 1.01
  • Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
  • Officer or director change Item 5.02
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Officer or director change Item 5.02
  • Officer or director change Item 5.02
  • Change of control Control of the company has changed hands. Item 5.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%